MET-097i is the lead investigational therapy from Metsera, designed as a fully biased GLP-1 receptor agonist with ultra-long-acting properties. Administered via SC injection, it leverages Metsera’s proprietary HALO platform and has shown a preliminary half-life of 15–16 days, indicating the potential for once-monthly dosing with flexible titration options.
Metsera shared clinical findings from the Phase I/II trial of MET-097i through two presentations, highlighting changes in body weight and tolerability outcomes following twelve weekly doses as well as a single monthly dose. The presentations are titled
A 12-week Trial of MET-097—A Potent and Ultra-Long-Ac...
